Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
Willing and able to provide written informed consent.
Aged 18 to 70 years, male or female.
Confirmed CD70 positive in tumor tissue by immunohistochemistry (IHC).
Peripheral T cell lymphoma (including peripheral T cell lymphoma NOS, angioimmunoblastic T cell lymphoma, anaplastic large cell lymphoma, etc.) who have failed ≥1 line of systemic therapy.
History or presence of CNS metastasis, or clinically relevant CNS pathology such as seizure, stroke, severe brain injury, etc.
History of solid organ transplantation.
Prior treatment with CD70-targeting agents.
Prior treatment with CAR-T or other cellular/gene therapies.
Tianjin Medical University Cancer Institute and Hospital
Lead sponsor
Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.
Collaborator